Your browser doesn't support javascript.
loading
Circulating miRNA-21 is an innovative biomarker for cardiovascular events in erectile dysfunction patients.
Agulló, Laura; Segura, Ana; Ortuño-Miquel, Samanta; Brinca, Ana Teresa; Micol-Ponce, Rosa; Arrarte, Vicente; Ponce, María Rosa; Miró-Martínez, Pau; Zandonai, Thomas; Peiró, Ana M.
  • Agulló L; Pharmacogenetic Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Dr. Balmis General University Hospital, Alicante, Spain.
  • Segura A; Institute of Bioengineering, Miguel Hernández University, Elche, Spain.
  • Ortuño-Miquel S; Andrology Unit, Urology Department, Dr. Balmis General University Hospital, Alicante, Spain.
  • Brinca AT; Bioinformatics Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Dr. Balmis General University Hospital, Alicante, Spain.
  • Micol-Ponce R; Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.
  • Arrarte V; Institute of Bioengineering, Miguel Hernández University, Elche, Spain.
  • Ponce MR; Cardiology Department, Dr. Balmis General University Hospital, Alicante, Spain.
  • Miró-Martínez P; Institute of Bioengineering, Miguel Hernández University, Elche, Spain.
  • Zandonai T; Department of Statistics and Operational Research of the Alcoy Campus of Universitat Politècnica de València, Alicante, Spain.
  • Peiró AM; Pharmacogenetic Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Dr. Balmis General University Hospital, Alicante, Spain.
Front Cardiovasc Med ; 11: 1301925, 2024.
Article en En | MEDLINE | ID: mdl-38576420
ABSTRACT

Introduction:

It is well-known that circulating microRNAs (miRNAs) play a relevant role in many kinds of diseases by regulating the expression of genes involved in various pathophysiologic processes, including erectile dysfunction (ED) and cardiovascular diseases (CVD).

Purpose:

This study aimed to identify the miRNA-21 profile in the blood samples of patients with ED, CVD, and the combination of both pathologies to elucidate the potential function of miRNA-21.

Methods:

A total of 45 patients with CVD and/or who underwent the erectile function test were included and divided into the following categories CVD with ED (cases, n = 29) and controls (n = 16) with either ED or CVD. Real-time polymerase chain reaction analysis verified the results. miRNA-21 expression was quantified, and informatics analysis was applied to predict the functions of this differentially expressed miRNA-21.

Results:

A total of 64% of cases (63 ± 9 years, 66% with severe ED, 56% with CV ejection fraction) first presented ED as the sentinel clinical manifestation. Serum miRNA-21 levels in the control ED were significant, up to 10-fold higher than in the CVD controls and cases. A significant inverse (p = 0.0368, ß = -2.046) correlation was found between erectile function and miRNA-21 levels.

Conclusions:

Our study provides comprehensive insights into the functional interaction between miRNA-21 and ED in CVD patients. Its relevance lies in the potential of miRNA as a biomarker to be applied in the cardiovascular predictive medicine field.
Palabras clave